A high CD8(+)/FOXP3(+) ratio and a high CD8(+) T cell count are both associated with favorable recurrence-free survival (RFS) and breast cancer-specific survival (BCSS) in a cohort of triple-negative breast cancer (TNBC) patients that received neoadjuvant chemotherapy (the majority received the standard regimen including anthracyclines and taxanes) [19]. This evidence concerns the gene CD8A and breast cancer.